Karuna Therapeutics

Karuna Therapeutics, a biopharmaceutical company founded in 2009, is making waves in the healthcare industry with its groundbreaking approach to treating mental illness. With the slogan "Pushing the boundaries of neuroscience to transform the treatment of mental illness," Karuna Therapeutics has garnered significant attention. In March 2023, the company received a remarkable $460.00M Post-IPO Equity investment, marking a pivotal moment for its growth and development. Notably, Karuna Therapeutics recently became a part of Bristol Myers Squibb, a move that signifies a new chapter in the company's journey of transforming the lives of patients with neurological and neuropsychiatric diseases. Through this partnership, the company is poised to amplify its impact and reach, positioning itself as a key player in the biopharma and healthcare sectors. The company's relentless commitment to pushing the boundaries of neuroscience sets it apart in the industry, promising innovative solutions to addressing mental health challenges. With its headquarters based in the United States, Karuna Therapeutics continues to drive forward, leveraging its expertise and resources to create meaningful change in the field of mental healthcare. For more information on the company's ongoing endeavors and its collaboration with Bristol Myers Squibb, visit their website at www.bms.com.